Treatment of childhood Hodgkin's disease with ABVD without radiotherapy

Med Pediatr Oncol. 1996 Apr;26(4):244-8. doi: 10.1002/(SICI)1096-911X(199604)26:4<244::AID-MPO4>3.0.CO;2-J.

Abstract

Seventeen previously untreated children with Hodgkin's disease were treated with six courses of the combination adriamycin, bleomycin, vinblastine, and DTIC (ABVD), without radiotherapy, from 1984-1987. In all patients, complete remission was attained. After a median follow-up period of 73.5 months (range 59-98 months) five patients had a relapse after 4, 5, 11, 21, and 34 months, respectively, from attainment of complete remission. In 12 patients with stages I and II, two relapses occurred. Three out of five patients with stage III and stage IV developed a relapse. Based upon these results, we conclude that ABVD might be an appropriate treatment for newly diagnosed children with Hodgkin's disease stages I and II. However, for children with stages III and IV more intensive treatment is needed. Radio-therapy should be withheld for children with refractory disease, residual disease, or relapse.

MeSH terms

  • Adolescent
  • Antibiotics, Antineoplastic / administration & dosage*
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents, Phytogenic / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bleomycin / administration & dosage*
  • Child
  • Child, Preschool
  • Cohort Studies
  • Dacarbazine / administration & dosage*
  • Disease-Free Survival
  • Doxorubicin / administration & dosage*
  • Female
  • Follow-Up Studies
  • Hodgkin Disease / drug therapy*
  • Hodgkin Disease / pathology
  • Humans
  • Male
  • Neoplasm Recurrence, Local
  • Neoplasm Staging
  • Neoplasm, Residual
  • Radiotherapy, Adjuvant
  • Remission Induction
  • Survival Rate
  • Vinblastine / administration & dosage*

Substances

  • Antibiotics, Antineoplastic
  • Antineoplastic Agents
  • Antineoplastic Agents, Phytogenic
  • Bleomycin
  • Vinblastine
  • Dacarbazine
  • Doxorubicin